These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26347108)

  • 1. High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers.
    Castro E; Jugurnauth-Little S; Karlsson Q; Al-Shahrour F; Piñeiro-Yañez E; Van de Poll F; Leongamornlert D; Dadaev T; Govindasami K; Guy M; Eeles R; Kote-Jarai Z;
    Ann Oncol; 2015 Nov; 26(11):2293-300. PubMed ID: 26347108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.
    Lozano R; Castro E; Lopez-Campos F; Thorne H; Ramirez-Backhaus M; Aragon IM; Cendón-Florez Y; Gutierrez-Pecharroman A; Salles DC; Romero-Laorden N; Lorente D; González-Peramato P; Calatrava A; Alonso C; Anido U; Arévalo-Lobera S; Balmaña J; Chirivella I; Juan-Fita MJ; Llort G; Y Cajal TR; Almagro E; Alameda D; López-Casas PP; Herrera B; Mateo J; Pritchard CC; Antonarakis ES; Lotan TL; Rubio-Briones J; Sandhu S; Olmos D
    Eur J Cancer; 2023 May; 185():105-118. PubMed ID: 36972661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
    Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
    Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
    Willems-Jones A; Kavanagh L; Clouston D; Bolton D; ; Fox S; Thorne H
    BJU Int; 2012 Dec; 110(11 Pt C):E1181-6. PubMed ID: 23035815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.
    Taylor RA; Fraser M; Livingstone J; Espiritu SM; Thorne H; Huang V; Lo W; Shiah YJ; Yamaguchi TN; Sliwinski A; Horsburgh S; Meng A; Heisler LE; Yu N; Yousif F; Papargiris M; Lawrence MG; Timms L; Murphy DG; Frydenberg M; Hopkins JF; Bolton D; Clouston D; McPherson JD; van der Kwast T; Boutros PC; Risbridger GP; Bristow RG
    Nat Commun; 2017 Jan; 8():13671. PubMed ID: 28067867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
    Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
    Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers.
    Gleicher S; Kauffman EC; Kotula L; Bratslavsky G; Vourganti S
    Prostate; 2016 Sep; 76(13):1135-45. PubMed ID: 27225637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.
    Seed G; Yuan W; Mateo J; Carreira S; Bertan C; Lambros M; Boysen G; Ferraldeschi R; Miranda S; Figueiredo I; Riisnaes R; Crespo M; Rodrigues DN; Talevich E; Robinson DR; Kunju LP; Wu YM; Lonigro R; Sandhu S; Chinnaiyan AM; de Bono JS
    Clin Cancer Res; 2017 Oct; 23(20):6070-6077. PubMed ID: 28751446
    [No Abstract]   [Full Text] [Related]  

  • 9. Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.
    Lozano R; Salles DC; Sandhu S; Aragón IM; Thorne H; López-Campos F; Rubio-Briones J; Gutierrez-Pecharroman AM; Maldonado L; di Domenico T; Sanz A; Prieto JD; García I; Pacheco MI; Garcés T; Llacer C; Romero-Laorden N; Zambrana F; López-Casas PP; Lorente D; Mateo J; Pritchard CC; Antonarakis ES; Olmos D; Lotan TL; Castro E
    Eur J Cancer; 2021 Apr; 147():74-83. PubMed ID: 33626496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
    Lotan TL; Kaur HB; Salles DC; Murali S; Schaeffer EM; Lanchbury JS; Isaacs WB; Brown R; Richardson AL; Cussenot O; Cancel-Tassin G; Timms KM; Antonarakis ES
    Mod Pathol; 2021 Jun; 34(6):1185-1193. PubMed ID: 33462368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.
    Edwards SM; Evans DG; Hope Q; Norman AR; Barbachano Y; Bullock S; Kote-Jarai Z; Meitz J; Falconer A; Osin P; Fisher C; Guy M; Jhavar SG; Hall AL; O'Brien LT; Gehr-Swain BN; Wilkinson RA; Forrest MS; Dearnaley DP; Ardern-Jones AT; Page EC; Easton DF; Eeles RA;
    Br J Cancer; 2010 Sep; 103(6):918-24. PubMed ID: 20736950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
    Castro E; Goh C; Olmos D; Saunders E; Leongamornlert D; Tymrakiewicz M; Mahmud N; Dadaev T; Govindasami K; Guy M; Sawyer E; Wilkinson R; Ardern-Jones A; Ellis S; Frost D; Peock S; Evans DG; Tischkowitz M; Cole T; Davidson R; Eccles D; Brewer C; Douglas F; Porteous ME; Donaldson A; Dorkins H; Izatt L; Cook J; Hodgson S; Kennedy MJ; Side LE; Eason J; Murray A; Antoniou AC; Easton DF; Kote-Jarai Z; Eeles R
    J Clin Oncol; 2013 May; 31(14):1748-57. PubMed ID: 23569316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.
    Willems AJ; Dawson SJ; Samaratunga H; De Luca A; Antill YC; Hopper JL; Thorne HJ;
    Clin Cancer Res; 2008 May; 14(10):2953-61. PubMed ID: 18445692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers.
    Mitra AV; Jameson C; Barbachano Y; Sodha N; Kote-Jarai Z; Javed A; Bancroft E; Fletcher A; Cooper C; Peock S; ; Easton D; Eeles R; Foster CS
    Oncol Rep; 2010 Feb; 23(2):299-305. PubMed ID: 20043088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations.
    Maier C; Herkommer K; Luedeke M; Rinckleb A; Schrader M; Vogel W
    Prostate; 2014 Oct; 74(14):1444-51. PubMed ID: 25111659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers.
    Adem C; Soderberg CL; Hafner K; Reynolds C; Slezak JM; Sinclair CS; Sellers TA; Schaid DJ; Couch F; Hartmann LC; Jenkins RB
    Genes Chromosomes Cancer; 2004 Sep; 41(1):1-11. PubMed ID: 15236312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
    Na R; Zheng SL; Han M; Yu H; Jiang D; Shah S; Ewing CM; Zhang L; Novakovic K; Petkewicz J; Gulukota K; Helseth DL; Quinn M; Humphries E; Wiley KE; Isaacs SD; Wu Y; Liu X; Zhang N; Wang CH; Khandekar J; Hulick PJ; Shevrin DH; Cooney KA; Shen Z; Partin AW; Carter HB; Carducci MA; Eisenberger MA; Denmeade SR; McGuire M; Walsh PC; Helfand BT; Brendler CB; Ding Q; Xu J; Isaacs WB
    Eur Urol; 2017 May; 71(5):740-747. PubMed ID: 27989354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer.
    Cui M; Gao XS; Gu X; Guo W; Li X; Ma M; Qin S; Qi X; Xie M; Peng C; Bai Y
    Oncotarget; 2017 Jun; 8(25):40222-40232. PubMed ID: 28410213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors.
    Decker B; Karyadi DM; Davis BW; Karlins E; Tillmans LS; Stanford JL; Thibodeau SN; Ostrander EA
    Am J Hum Genet; 2016 May; 98(5):818-829. PubMed ID: 27087322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.